Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 44.7% in February

Vigil Neuroscience, Inc. (NASDAQ:VIGL) saw a significant drop in short interest in February. As of February 28th, there was short interest totalling 564,000 shares, a drop of 44.7% from the February 13th total of 1,020,000 shares. Approximately 2.9% of the company’s stock are short sold. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is currently 0.5 days.

Hedge Funds Weigh In On Vigil Neuroscience

Several hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC grew its position in shares of Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock valued at $41,000 after purchasing an additional 8,358 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock worth $110,000 after buying an additional 14,572 shares during the period. Barclays PLC increased its holdings in shares of Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company’s stock worth $109,000 after buying an additional 19,436 shares during the period. Two Sigma Investments LP increased its holdings in shares of Vigil Neuroscience by 44.0% in the fourth quarter. Two Sigma Investments LP now owns 136,920 shares of the company’s stock worth $233,000 after buying an additional 41,836 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of Vigil Neuroscience in the fourth quarter worth about $83,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Vigil Neuroscience Trading Down 4.3 %

Shares of VIGL opened at $2.02 on Friday. The stock has a 50 day moving average of $2.34 and a 200 day moving average of $2.79. Vigil Neuroscience has a 12 month low of $1.49 and a 12 month high of $6.06. The company has a market capitalization of $82.58 million, a price-to-earnings ratio of -0.98 and a beta of 1.82.

Vigil Neuroscience (NASDAQ:VIGL) last released its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). As a group, equities research analysts predict that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VIGL has been the topic of a number of recent research reports. Guggenheim restated a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. HC Wainwright dropped their target price on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Friday. Wedbush decreased their price target on Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday. William Blair began coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They set an “outperform” rating for the company. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $16.25.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.